medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2014, Number 3

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2014; 30 (3)

Obtention of cell culture supernatant for erythrocyte agglutination of blood group B antigen

Miranda AA, Justiz LAC, Mures DYL, Romaguera FY

Language: Spanish
References: 13
Page: 248-256
PDF size: 137.20 Kb.


ABSTRACT

Introduction: The obtention of monoclonal antibodies in ascite fluid has been declining gradually due to the appearance of alternative in vitro production that achieve higher volumes and a more precise monitoring of the production process, which increases the reproducibility of processes and the quality of products.
Objective: To evaluate two methods to make cell culture supernatant rich in murine monoclonal IgG2b type, with agglutinating activity against human red cell of blood group antigen B (ABO system), which is secreted by murine hybridoma C6G4.
Methods: Two methods were evaluated for antibody production in cell culture supernatant using as model a CELLine bioreactor for the production of monoclonal antibodies in high cell density culture. Both methods essentially differed in the seeding cell density in the bioreactor and the fermentation period between seeding and harvesting of the culture broth rich in antibodies. The specific antibody concentration and potency of agglutination was determined in the obtained supernatant and also the cell density and cell viability of the culture reached at the time of harvest.
Results: Both methods generated culture supernatants with similar agglutination strength despite differences found in the rest of the variables measured. Even when one of the methods produced a higher antibody concentration in the supernatants, no differences in potency of the supernatants agglutination obtained by both alternatives were observed.
Conclusions: Both methods generated supernatant anti-B with different concentrations of antibodies but similar potency of agglutination. The main difference was that with one of the methods the same volume of the product was obtained in a considerably minor time.


REFERENCES

  1. Zhang C. Hybridoma technology for the generation of monoclonal antibodies. En: Proetzel G, Ebersbach H, Editores. Antibody Methods and Protocols. New York: Humana Press; 2012. p. 117-35.

  2. Vermasvuori R, HurmeM. Economic comparison of diagnostic antibody production in perfusion stirred tank and in hollow fiber bioreactor processes. Biotechnol Prog. 2011 Nov-Dec;27(6):1588-98.

  3. Hendriksen CF, de Leeuw W. Production of monoclonal antibodies by the ascites method in laboratory animals. Res Immunol. 1998 Jul-Aug;149(6):535-42.

  4. Bareither R, Pollard D. A review of advanced small scale-parallel bioreactor technology for accelerated process development: Current state and future need. BiotechnolProg. 2011 Jan-Feb;27(1):2-14.

  5. Karuppaiya A, Cheah SH, Mohd S, Kamal WH, Zulkifli MH. Generation and characterization of monoclonal antibodies against prostate-specific antigen. Hybridoma (Larchmt). 2009 Apr;28(2):133-7.

  6. Eibl R, Kaiser S, Lombriser R, Eibl D. Disposable bioreactors; the current stateof- the-art and recommended applications in biotechnology. Appl Microbiol Biotechnol. 2010 Mar;86(1):41-9.

  7. Trujillo-Roldán MA, Valdez-Cruz NA. El uso de biorreactores desechables en la industria biofarmacéutica y sus implicaciones en la ingeniería. Dyna. 2009 Jun;76(158):275-83.

  8. Diekmann S, Dürr C, Herrmann A, Lindner I, Jozic D, ed. Single use bioreactors for the clinical production of monoclonal antibodies-a study to analyze the performance of a CHO cell line and the quality of the produced monoclonal antibody. BMC Proceedings. 2011 Nov 22;5(8):103.

  9. Bruce MP, Boyd V, Duch C, White JR. Dialysis-based bioreactorsystems for the production of monoclonal antibodies. Alternatives toascites production in mice. J Immunol Methods. 2002 Jun 1;264(1-2):59-68.

  10. Mittermaier J, Zang-Gandor MO. Long-Term High Level Protein Expression in Adherent, Protein-free Growing BHK Cells Using INTEGRA CELLine adhere 1000 Bioreactor Flasks. Genetic Engineering News. 2004;24(12):42.

  11. Schlaeger EJ, Eggimann B, Gast A. Proteolytic activity in the culture supernatants of mouse hybridoma cells. DevBiol Stand. 1987;66:403-8.

  12. Spens E, Häggström L. Protease activity in protein-free NS0 myeloma cell cultures in vitro cell. DevBiolAnim. 2005 Nov-Dec;41(10):330-6.

  13. CELLine Operating instructions. INTEGRA Biosciences. [citado 11 jun 2013]. Disponible en: http://www.integrabiosciences. com/sites/pdf/operating_instructions/90100_V04_OI_CELLine_EN.pdf




2020     |     www.medigraphic.com